The Safety and Efficacy of a Therapeutic Vaccine for Chronic Hepatitis B: A Follow-Up Study of Phase III Clinical Trial

被引:14
作者
Akbar, Sheikh Mohammad Fazle [1 ]
Al Mahtab, Mamun [2 ]
Aguilar, Julio Cesar [3 ]
Yoshida, Osamu [1 ]
Khan, Sakirul [4 ]
Penton, Eduardo [3 ]
Gerardo, Guillen Nieto [3 ]
Hiasa, Yoichi [1 ]
机构
[1] Ehime Univ, Grad Sch Med, Dept Gastroenterol & Metabol, Toon 7910295, Japan
[2] Bangabandhu Sheikh Mujib Med Univ BSMMU, Dept Hepatol, Dhaka 1000, Bangladesh
[3] Ctr Genet Engn & Biotechnol, Havana 10600, Cuba
[4] Oita Univ, Fac Med, Dept Microbiol, Oita 8795593, Japan
关键词
chronic hepatitis B; therapeutic vaccine; HBsAg; HBcAg vaccine; NASVAC; nasal vaccine; follow-up; CORE ANTIGEN; SURFACE; CANDIDATE; CELLS; HBCAG;
D O I
10.3390/vaccines10010045
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The objective of the present study was to assess the safety and efficacy of a therapeutic vaccine containing both HBsAg and HBcAg (NASVAC) in patients with chronic hepatitis B (CHB) three years after the end of treatment (EOT) as a follow-up of a phase III clinical trial. NASVAC was administered ten times by the nasal route and five times by subcutaneous injection. A total of 59 patients with CHB were enrolled. Adverse events were not seen in any of the patients. Out of the 59 CHB patients, 54 patients exhibited a reduction in HBV DNA, compared with their basal levels. Although all the patients had alanine transaminase (ALT) above the upper limit of normal (>42 IU/L) before the commencement of therapy, the levels of ALT were within the ULN level in 42 patients. No patient developed cirrhosis of the liver. The present study, showing the safety and efficacy of NASVAC 3 years after the EOT, is the first to report follow-up data of an immune therapeutic agent against CHB. NASVAC represents a unique drug against CHB that is safe, of finite duration, can be administered by the nasal route, is capable of reducing HBV DNA and normalizing ALT, and contains hepatic fibrosis.
引用
收藏
页数:9
相关论文
共 21 条
[1]   Sustained Antiviral and Liver Protection by a Nasal Therapeutic Vaccine (NASVAC, Containing Both HBsAg and HBcAg) in Patients with Chronic Hepatitis B: 2-Year Follow-Up of Phase III Clinical Trial [J].
Akbar, Sheikh Mohammad Fazle ;
Al Mahtab, Mamun ;
Aguilar, Julio Cesar ;
Yoshida, Osamu ;
Penton, Eduardo ;
Gerardo, Guillen Nieto ;
Hiasa, Yoichi .
PATHOGENS, 2021, 10 (11)
[2]   Implications of Birth-Dose Vaccination against Hepatitis B Virus in Southeast Asia [J].
Akbar, Sheikh Mohammad Fazle ;
Al Mahtab, Mamun ;
Begum, Ferdousi ;
Hossain, Shaikh A. Shahed ;
Sarker, Sukumar ;
Shrestha, Ananta ;
Khan, Md Sakirul Islam ;
Yoshida, Osamu ;
Hiasa, Yoichi .
VACCINES, 2021, 9 (04)
[3]   Strong and multi-antigen specific immunity by hepatitis B core antigen (HBcAg)-based vaccines in a murine model of chronic hepatitis B: HBcAg is a candidate for a therapeutic vaccine against hepatitis B virus [J].
Akbar, Sheikh Mohammad Fazle ;
Chen, Shiyi ;
Al-Mahtab, Mamun ;
Abe, Masanori ;
Hiasa, Yoichi ;
Onji, Morikazu .
ANTIVIRAL RESEARCH, 2012, 96 (01) :59-64
[4]   Immune modulator and antiviral potential of dendritic cells pulsed with both hepatitis B surface antigen and core antigen for treating chronic HBV infection [J].
Akbar, Sheikh Mohammad Fazle ;
Yoshida, Osamu ;
Chen, Shiyi ;
Cesar, Aguilar Julio ;
Abe, Masanori ;
Matsuura, Bunzo ;
Hiasa, Yoichi ;
Onji, Morikazu .
ANTIVIRAL THERAPY, 2010, 15 (06) :887-895
[5]   Treatment of chronic hepatitis B naive patients with a therapeutic vaccine containing HBs and HBc antigens (a randomized, open and treatment controlled phase III clinical trial) [J].
Al Mahtab, Mamun ;
Akbar, Sheikh Mohammad Fazle ;
Aguilar, Julio Cesar ;
Guillen, Gerardo ;
Penton, Euduaro ;
Tuero, Angela ;
Yoshida, Osamu ;
Hiasa, Yoichi ;
Onji, Morikazu .
PLOS ONE, 2018, 13 (08)
[6]   Therapeutic potential of a combined hepatitis B virus surface and core antigen vaccine in patients with chronic hepatitis B [J].
Al-Mahtab, Mamun ;
Akbar, Sheikh Mohammad Fazle ;
Aguilar, Julio Cesar ;
Uddin, Md. Helal ;
Khan, Md. Sakirul Islam ;
Rahman, Salimur .
HEPATOLOGY INTERNATIONAL, 2013, 7 (04) :981-989
[7]   Phase I clinical trial in healthy adults of a nasal vaccine candidate containing recombinant hepatitis B surface and core antigens [J].
Betancourt, Aristides Aguilar ;
Delgado, C. A. Gonzalez ;
Estevez, Z. Cinza ;
Martinez, J. Cabrera ;
Rios, G. Veliz ;
Aureoles-Rosello, S. R. Moreno ;
Zaldivar, R. Aleman ;
Guzman, M. Alonso ;
Baile, N. Figueroa ;
Reyes, P. A. Dias ;
Ruano, L. Olivera ;
Fernandez, A. Correa ;
Lobaina-Matos, Y. ;
Fernandez, A. Delahanty ;
Madrazo, A. I. Juvier ;
Martinez, M. I. Alonso ;
Banos, M. Lago ;
Alvarez, N. Puble ;
Baldo, M. David ;
Mestre, R. E. Soto ;
Perez, M. V. Perez ;
Martinez, M. E. Pena ;
Escobar, D. Acosta ;
Guanche, M. J. Cerna ;
Caceres, L. Mila ;
Betancourt, R. Sanchez ;
Rando, E. Hardy ;
Nieto, G. E. Guillen ;
Gonzalez, V. L. Muzio ;
Rubido, J. C. Aguilar .
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2007, 11 (05) :394-401
[8]   HBV Immune-Therapy: From Molecular Mechanisms to Clinical Applications [J].
Boni, Carolina ;
Barili, Valeria ;
Acerbi, Greta ;
Rossi, Marzia ;
Vecchi, Andrea ;
Laccabue, Diletta ;
Penna, Amalia ;
Missale, Gabriele ;
Ferrari, Carlo ;
Fisicaro, Paola .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (11)
[9]   EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection [J].
Lampertico P. ;
Agarwal K. ;
Berg T. ;
Buti M. ;
Janssen H.L.A. ;
Papatheodoridis G. ;
Zoulim F. ;
Tacke F. .
JOURNAL OF HEPATOLOGY, 2017, 67 (02) :370-398
[10]   Limited sustained response after stopping nucleos(t)ide analogues in patients with chronic hepatitis B: results from a randomised controlled trial (Toronto STOP study) [J].
Liem, Kin Seng ;
Fung, Scott ;
Wong, David K. ;
Yim, Colina ;
Noureldin, Seham ;
Chen, Jiayun ;
Feld, Jordan J. ;
Hansen, Bettina E. ;
Janssen, Harry L. A. .
GUT, 2019, 68 (12) :2206-2213